Combination chemotherapy for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs (irinotecan liposome, capecitabine, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has grown despite previous treatment. The goal is to see if this new combination can help shrink tumors or slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced or unresectable bile duct or gallbladder cancer, and it must have progressed after at least one prior treatment.
- You must not have previously taken capecitabine or lenvatinib.
- You must be in generally good health (able to do light work and get out of bed most of the day).
- You must not have uncontrolled infections, serious heart problems, or a history of brain metastases.
- Your major organs (bone marrow, liver, kidneys) must be functioning well enough to safely receive the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. Combining immunotherapy with chemotherapy may help shrink tumors and slow the cancer's growth.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
Hear when a new Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.